Skip to content
2000
  1. Home
  2. A-Z Publications
  3. CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders)
  4. Volume 23, Issue 12
  5. Article
Volume 23, Issue 12
  • ISSN: 1871-5273
  • E-ISSN:

Abstract

Background

Recently, US Food and Drug Administration (FDA) has approved calcitonin gene-related peptide receptor antagonists (rimegepant, and ubrogepant), and selective serotonin receptor agonists (lasmiditan) in the management of migraine. However, the exact safety and efficacy profile of these drugs is unclear so far.

Methods

The study’s primary objective was to determine the exact safety and efficacy profile. The overall estimate was calculated in terms of risk ratios using a suitable model. The subgroup analysis was also performed to check the effect of individual drugs on the outcome, whereas sensitivity analysis was performed to check the effects of outliers on the outcome. All the analyses were performed using Rev Man 5. The drugs have shown significant improvement in efficacy parameters (pain freedom, most bothersome symptoms, phonophobia, nausea, and photophobia).

Results

The subgroup analysis results have shown significant improvement in all efficacy parameters in the rimegepant and ubrogepant groups. The effect of ubrogepant on safety parameters was found to be non-significant, indicating a better safety profile of ubrogepant than lasmiditan.

Conclusion

The sensitivity analysis results have shown no effect of outliers on the efficacy parameters. Based on the available evidence, recently approved drugs are effective in the treatment of migraine, however, associated with few adverse drug reactions.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cnsnddt/10.2174/0118715273304677240529062909
2024-12-01
2024-11-15

  • From This Site

    /content/journals/cnsnddt/10.2174/0118715273304677240529062909
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. PetersG.L. Migraine overview and summary of current and emerging treatment options.Am. J. Manag. Care2019252Suppl.S23S34 30681821
     [Google Scholar]
  2. StewartW.F. LiptonR.B. LibermanJ. Variation in migraine prevalence by race.Neurology1996471525910.1212/WNL.47.1.52 8710124
     [Google Scholar]
  3. LiptonR.B. BigalM.E. The epidemiology of migraine.Am. J. Med.2005118Suppl. 13S10S 15841882
     [Google Scholar]
  4. LiptonR.B. StewartW.F. DiamondS. DiamondM.L. ReedM. Prevalence and burden of migraine in the United States: Data from the American Migraine Study II.Headache200141764665710.1046/j.1526‑4610.2001.041007646.x 11554952
     [Google Scholar]
  5. AshinaM. KatsaravaZ. DoT.P. Migraine: Epidemiology and systems of care.Lancet2021397102831485149510.1016/S0140‑6736(20)32160‑7 33773613
     [Google Scholar]
  6. AgostoniE.C. BarbantiP. CalabresiP. Current and emerging evidence-based treatment options in chronic migraine: A narrative review.J. Headache Pain20192019210.1186/s10194‑019‑1038‑4 31470791
     [Google Scholar]
  7. CroopR. GoadsbyP.J. StockD.A. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: A randomised, phase 3, double-blind, placebo-controlled trial.Lancet20193941020073774510.1016/S0140‑6736(19)31606‑X 31311674
     [Google Scholar]
  8. GoadsbyP.J. BlumenfeldA.M. LiptonR.B. Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications.Cephalalgia202141554656010.1177/0333102420970523 33241721
     [Google Scholar]
  9. KucaB. SilbersteinS.D. WietechaL. Lasmiditan is an effective acute treatment for migraine.Neurology20189124e2222e223210.1212/WNL.0000000000006641 30446595
     [Google Scholar]
  10. PrakashS. RanaK. Lasmiditan: A new promising drug in migraine.Ann. Indian Acad. Neurol.202124212612710.4103/aian.AIAN_30_21 34220050
     [Google Scholar]
  11. HaidichA.B. Meta-analysis in medical research.Hippokratia201014Suppl. 12937 21487488
     [Google Scholar]
  12. National Heart Lung and Blood Institute (NIH)Study quality assessment tools.Available From: https://www.nhlbi.nih.gov/ 2023
     [Google Scholar]
  13. JohnstonK.M. PowellL. PopoffE. Rimegepant, ubrogepant, and lasmiditan in the acute treatment of migraine examining the benefit-risk profile using number needed to treat/harm.Clin. J. Pain2022381168068510.1097/AJP.0000000000001072 36125279
     [Google Scholar]
  14. JakateA. BoinpallyR. ButlerM. LuK. McGeeneyD. PericlouA. Evaluation of the pharmacokinetic interaction of ubrogepant coadministered with sumatriptan and of the safety of ubrogepant with triptans.Headache20206071340135010.1111/head.13862 32573795
     [Google Scholar]
  15. ClemowD.B. HochstetlerH.M. DongY. HauckP. PeresM.F.P. AilaniJ. Effect of a change in lasmiditan dose on efficacy and safety in patients with migraine.Postgrad. Med.2021133444945910.1080/00325481.2020.1860619 33730977
     [Google Scholar]
  16. DodickD.W. LiptonR.B. AilaniJ. Ubrogepant, an acute treatment for migraine, improved patient-reported functional disability and satisfaction in 2 single-attack phase 3 randomized trials, achieve I and II.Headache202060468670010.1111/head.13766 32073660
     [Google Scholar]
  17. DodickD.W. LiptonR.B. AilaniJ. Ubrogepant for the treatment of migraine.N. Engl. J. Med.2019381232230224110.1056/NEJMoa1813049 31800988
     [Google Scholar]
  18. KregeJ.H. RizzoliP.B. LiffickE. Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN.Cephalalgia201939895796610.1177/0333102419855080 31166697
     [Google Scholar]
  19. KnievelK. BuchananA.S. LombardL. Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans.Cephalalgia2020401192710.1177/0333102419889350 31744319
     [Google Scholar]
  20. LooL.S. PlatoB.M. TurnerI.M. Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: Findings from the phase 3 trials (SAMURAI and SPARTAN).BMC Neurol.201919119110.1186/s12883‑019‑1420‑5 31409292
     [Google Scholar]
  21. FärkkiläM. DienerH.C. GéraudG. Efficacy and tolerability of lasmiditan, an oral 5-HT1F receptor agonist, for the acute treatment of migraine: A phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study.Lancet Neurol.201211540541310.1016/S1474‑4422(12)70047‑9 22459549
     [Google Scholar]
  22. AshinaM. VasudevaR. JinL. Onset of efficacy following oral treatment with lasmiditan for the acute treatment of migraine: Integrated results from 2 randomized double-blind placebo-controlled phase 3 clinical studies.Headache201959101788180110.1111/head.13636 31529622
     [Google Scholar]
  23. LiptonR.B. CroopR. StockE.G. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine.N. Engl. J. Med.2019381214214910.1056/NEJMoa1811090 31291516
     [Google Scholar]
  24. LiptonR.B. DodickD.W. AilaniJ. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: The ACHIEVE II randomized clinical trial.JAMA2019322191887189810.1001/jama.2019.16711 31742631
     [Google Scholar]
  25. CroopR. LiptonR.B. KudrowD. Oral rimegepant for preventive treatment of migraine: A phase 2/3, randomised, double-blind, placebo-controlled trial.Lancet202139710268516010.1016/S0140‑6736(20)32544‑7 33338437
     [Google Scholar]
  26. ShapiroR.E. HochstetlerH.M. DennehyE.B. Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: Post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials.J. Headache Pain20192019010.1186/s10194‑019‑1044‑6 31464581
     [Google Scholar]
  27. MarcusR. GoadsbyP.J. DodickD. StockD. ManosG. FischerT.Z. BMS-927711 for the acute treatment of migraine: A double-blind, randomized, placebo controlled, dose-ranging trial.Cephalalgia201434211412510.1177/0333102413500727 23965396
     [Google Scholar]
  28. VossT. LiptonR.B. DodickD.W. A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine.Cephalalgia201636988789810.1177/0333102416653233 27269043
     [Google Scholar]
  29. TepperS.J. VasudevaR. KregeJ.H. Evaluation of 2-hour post-dose efficacy of lasmiditan for the acute treatment of difficult-to-treat migraine attacks.Headache20206081601161510.1111/head.13897 32634275
     [Google Scholar]
  30. TepperS.J. KregeJ.H. LombardL. Characterization of dizziness after lasmiditan usage: Findings from the SAMURAI and SPARTAN acute migraine treatment randomized trials.Headache20195971052106210.1111/head.13544 31152441
     [Google Scholar]
  31. SakaiF. TakeshimaT. HommaG. TanjiY. KatagiriH. KomoriM. Phase 2 randomized placebo‐controlled study of lasmiditan for the acute treatment of migraine in Japanese patients.Headache202161575576510.1111/head.14122 33990951
     [Google Scholar]
  32. WilbrahamD. BergP.H. TsaiM. Abuse potential of lasmiditan: A phase 1 randomized, placebo- and alprazolam-controlled crossover study.J. Clin. Pharmacol.202060449550410.1002/jcph.1543 31745991
     [Google Scholar]
  33. AshinaM. ReuterU. SmithT. Randomized, controlled trial of lasmiditan over four migraine attacks: Findings from the CENTURION study.Cephalalgia202141329430410.1177/0333102421989232 33541117
     [Google Scholar]
  34. HutchinsonS. SilbersteinS.D. BlumenfeldA.M. Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and II.Cephalalgia202141997999010.1177/03331024211000311 33874756
     [Google Scholar]
  35. BlumenfeldA.M. GoadsbyP.J. DodickD.W. Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis.Headache202161342242910.1111/head.14089 33749826
     [Google Scholar]
  36. ReuterU. KregeJ.H. LombardL. Lasmiditan efficacy in the acute treatment of migraine was independent of prior response to triptans: Findings from the CENTURION study.Cephalalgia2022421203010.1177/03331024211048507 34644189
     [Google Scholar]
  37. GoadsbyP.J. TepperS.J. WatkinsP.B. Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: Randomized, placebo-controlled trial in healthy adults.Cephalalgia201939141753176110.1177/0333102419869918 31537107
     [Google Scholar]
  38. GoadsbyP.J. WietechaL.A. DennehyE.B. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine.Brain201914271894190410.1093/brain/awz134 31132795
     [Google Scholar]
  39. LooL.S. AilaniJ. SchimJ. Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: Findings from SAMURAI and SPARTAN, two randomized phase 3 trials.J. Headache Pain20192018410.1186/s10194‑019‑1032‑x 31340760
     [Google Scholar]
  40. DotyE.G. KregeJ.H. JinL. RaskinJ. Halker SinghR.B. KalidasK. Sustained responses to lasmiditan: Results from post-hoc analyses of two Phase 3 randomized clinical trials for acute treatment of migraine.Cephalalgia201939121569157610.1177/0333102419859313 31266353
     [Google Scholar]
  41. LiptonR.B. LombardL. RuffD.D. Trajectory of migraine-related disability following long-term treatment with lasmiditan: Results of the GLADIATOR study.J. Headache Pain20202112010.1186/s10194‑020‑01088‑4 32093628
     [Google Scholar]
  42. HaD.K. KimM.J. HanN. KwakJ.H. BaekI. Comparative efficacy of oral calcitonin-gene-related peptide antagonists for the treatment of acute migraine: Updated meta-analysis.Clin. Drug Investig.202141211913210.1007/s40261‑020‑00997‑1 33426614
     [Google Scholar]
  43. RaposioE. RaposioG. Del DuchettoD. TagliattiE. CorteseK. Morphologic vascular anomalies detected during migraine surgery.J. Plast. Reconstr. Aesthet. Surg.202275114069407310.1016/j.bjps.2022.08.036 36167709
     [Google Scholar]
  44. HuangT. XuY. ChenY. Efficacy and safety of calcitonin gene‐related peptide antagonists in migraine treatment: A meta‐analysis.Brain Behav.2022124e254210.1002/brb3.2542 35261165
     [Google Scholar]
  45. D V, SharmaA KumarA FloraSJS Neurological manifestations in COVID-19 patients: A meta-analysis.ACS Chem. Neurosci.202112152776279710.1021/acschemneuro.1c00353 34260855
     [Google Scholar]
  46. MessinaR. GoadsbyP.J. CGRP – a target for acute therapy in migraine: Clinical data.Cephalalgia201939342042710.1177/0333102418768095 29616830
     [Google Scholar]
  47. HollandP.R. GoadsbyP.J. Targeted CGRP Small molecule antagonists for acute migraine therapy.Neurotherapeutics201815230431210.1007/s13311‑018‑0617‑4 29556965
     [Google Scholar]
  48. DoT.P. GuoS. AshinaM. Therapeutic novelties in migraine: New drugs, new hope?J. Headache Pain20192013710.1186/s10194‑019‑0974‑3 30995909
     [Google Scholar]
  49. HouM. XingH. LiC. Short-term efficacy and safety of lasmiditan, a novel 5-HT1F receptor agonist, for the acute treatment of migraine: A systematic review and meta-analysis.J. Headache Pain20202116610.1186/s10194‑020‑01138‑x 32503415
     [Google Scholar]
  50. YangC.P. LiangC.S. ChangC.M. Comparison of new pharmacologic agents with triptans for treatment of migraine: A systematic review and meta-analysis.JAMA Netw. Open2021410e212854410.1001/jamanetworkopen.2021.28544 34633423
     [Google Scholar]
  51. SrivastavaR. KumarA. Use of aspirin in reduction of mortality of COVID‐19 patients: A meta‐analysis.Int. J. Clin. Pract.20217511e1451510.1111/ijcp.14515 34118111
     [Google Scholar]
/content/journals/cnsnddt/10.2174/0118715273304677240529062909
Loading
Safety and Efficacy of Calcitonin Gene-related Peptide Receptor Antagonists and Selective Serotonin Receptor Agonist in the Management of Migraine: A Systematic Review and Meta-analysis
CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders) 23, 1474 (2024); https://doi.org/10.2174/0118715273304677240529062909
/content/journals/cnsnddt/10.2174/0118715273304677240529062909
/content/journals/cnsnddt/10.2174/0118715273304677240529062909
Loading

Data & Media loading...

Supplements

file format download Download

  • Article Type:     Research Article
Keyword(s): drug; lasmiditan; meta-analysis; Migraine; rimegepant; ubrogepant

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test